Viewpoint

The international treaty on plant genetic resources needs a gesture of trust to repair the atmosphere of suspicion that has developed, argues Emile Frison from the International Plant Genetic Resources Institute.

The TeGenero drug trial is complete, and an ongoing study is examing whether trial requirements should be changed. But, asks Nuala Moran, should the trial ever have been approved?

EU technology policy is moving beyond the numbers game, and getting down to economic basics.

Without access to easy to use analysis tools, patents are becoming an expensive hindrance to many small companies, says Mick McLean, Head of Economics and Public Policy at Scientific Generics.

AstraZeneca’s outrageously high bid for Cambridge Antibody Technology underscores the heat rising in the biotech market.

The European Research Council’s plan to give grants to young researchers could help in the reform of Europe’s sclerotic research structures.

A greener lifestyle is not inimical to economic growth, says the author of a new report on how green initiatives are triggers for innovation.

Spend more on basic research - that's one of the prescriptions for Europe offered by Jim Goodnight, founder and CEO of SAS, one of the world's largest privately held software companies.

Europe needs more "angel" investors to finance its start-ups. A Prague conference highlights why it isn't getting them.

The conclusion that there was nothing wrong with the specifics of the TeGenero trial in which six healthy volunteers ended up in intensive care has repercussions for the wider biotech industry.